Atrium Therapeutics, Inc.
RNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002093101
No open-market purchases or sales by Atrium Therapeutics, Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q2 2026, worth $192.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Atrium Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Atrium Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Younis Husam | Chief Scientific Officer | 41,441 | Sep 22, 2026 | 2 |
| Hughes Steven George | Chief Medical Officer | 51,638 | Sep 22, 2026 | 2 |
| Flanagan W. Michael | Director | 31,974 | Sep 22, 2026 | 2 |
| Boyce Sarah | Director | 138,668 | Sep 22, 2026 | 2 |
| Kenney Stephanie | See Remarks | 33,085 | Sep 22, 2026 | 2 |
| Gallagher Kathleen P. | See Remarks | 119,729 | Sep 22, 2026 | 2 |
| Winslow Brendan R. | Chief Financial Officer | 36,859 | Sep 22, 2026 | 2 |
| Hoyos Rocio Martin | Chief Strategy Officer | 38,340 | Sep 22, 2026 | 2 |
| Boess Carsten | Director | – | Mar 2, 2026 | 1 |
| Wilson Troy Edward | Director | – | Mar 2, 2026 | 1 |
| Skerjanec Simona | Director | – | Mar 2, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.